Journals / Ortadoğu Tıp Dergisi / 2015 / Cilt: 7 - Sayı: 1

Relationships Between Megaloblastic Anemia Due To Vıtamin B 12 Deficiency and Ca 15-3: A Case Report

B12 Vitamin Eksikliğine Bağlı Megaloblastik Anemi ile Ca 15-3 İlişkisi: Olgu Sunumu

Pages
43–45
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

With this case report we aimed to show, CA 15-3 levels may be associated withvitamin B12 level.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:CA 15-3 is a glycoprotein marker which increase in some cancers and benign diseases.
📊
Key Findings & Data:The most important causeof megaloblastic anemia is vitamin B12 and /or folate deficiency.
💡
Conclusion & Impact:With this case report we aimed to show, CA 15-3 levels may be associated withvitamin B12 level.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

CA 15-3 is a glycoprotein marker which increase in some cancers and benign diseases. The most important causeof megaloblastic anemia is vitamin B12 and /or folate deficiency. Fifty-seven-year-old male patient presented withweakness and fatigue. In the laboratory there were bicytopenia and vitamin B12 deficiency and CA 15-3 elevationwere detected. The patient was treated with cyanocobalamin 1000 µg intramuscular 1x1, after two weeks vitaminB12 was increased and CA15-3 levels decreased also. There are a five literatures about CA 15-3 and vitamin B12deficiency anemia relationships. With this case report we aimed to show, CA 15-3 levels may be associated withvitamin B12 level.

Özet

CA 15-3 bazı kanser ve iyi huylu hastalıklarda yükselebilen glikoprotein yapıda bir belirteçtir. Megaloblastik anemi- nin en yaygın sebebi vitamin B12 ve/veya folik asit eksikliğidir. Elli sekiz yaşında erkek hasta halsizlik ve yorgunlukşikâyeti ile başvurmuştu. Labaratuvar değerlendirmesinde; bisitopeni, B12 vitamin eksikliği ve CA 15-3 yüksekliğisaptandı. Hastaya siyanokobalamin 1000 µg 1x1 intramusküler tedavisi başlandı, iki hafta sonra B12 vitamin sevi- yeleri yükselmiş, CA 15-3 ise düşmüştü. CA 15-3 ve B12 vitamin eksikliği arasındaki ilişkiyi değerlendiren az sayı- da literatür mevcuttur. Bu olgu ile CA 15-3 seviyelerinin B12 vitamin dizeyi ile de ilişkili olabileceğini göstermeyiamaçladık.

🔖

Cite This Article

KOŞAR, A., BALÇIK, Ş., KEREN, F., TANRIKULU, E. Ş. (2022). Relationships Between Megaloblastic Anemia Due To Vıtamin B 12 Deficiency and Ca 15-3: A Case Report. Ortadoğu Tıp Dergisi, Cilt: 7 - Sayı: 1, 43–45. https://ajindex.com/articles/585863

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Pruthi RK, Tefferi A. Pernicious anemia revisited. Mayo Clin Proc 1994; 69:144-150
  2. Allen RH, Stabler SP, Savage DG, et al. Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency. FASEB J 1993; 7: 1344-1353
  3. Green R, Kinsella LJ. Current concepts in the diagnosis of Coba- lamin deficiency. Neurology 1995;45:1435-1440
  4. Duffy MJ, Evoy D, McDermott EW. CA 15-3: uses and limitations as a biomarker for breast cancer. Clin Chim Acta 2010; 411;23- 24;1869-1874
  5. Symeonidis A, Kouraklis-Symeonidis A, Apostolopoulos D, et al. Increased serum CA-15.3 levels in patients with megaloblas- tic anemia due to vitamin B12 deficiency. Oncology. 2004;67(5- 6):359-367
  6. Aslan V, Yavuz H, Durak B, ve ark. CA 15-3: Can used to diagnosis and differential diagnosis of megaloblastic anemia associated with vitamin B12 deficiency? Haematologica 2007; 92[suppl.2]:430: Abstract 1172
  7. Bay A, Öner AF, Nalbantoğlu Ö, ve ark. Megaloblastik Anemili 45 Olgunun Klinik ve Hematolojik Yönden Değerlendirilmesi. Van Tıp Dergisi: 2006;13 (2):46-48
  8. D'Elios MM, Appelmelk BJ, Amedei A, et al. Gastric autoim- munity: the role of Helicobacter pylori and molecular mimicry. Trends Mol Med 2004; 10(7):316-323
  9. Buchman N, Mendelsson E, Lerner V, et al. Delirium associated with vitamin B12 deficiency after pneumonia. Clin Neuropharma- col 1999; 22(6): 356-358.